| scholarly article | Q13442814 |
| P50 | author | Dawn L. Hershman | Q87128576 |
| P2093 | author name string | Scott D Ramsey | |
| Ruth Etzioni | |||
| William E Barlow | |||
| Diane P Martin | |||
| Joseph M Unger | |||
| Michael Leblanc | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 | ||
| Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population | Q30714715 | ||
| Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. | Q33384024 | ||
| A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). | Q33502338 | ||
| Ethical issues in the design and conduct of randomised controlled trials. | Q33588994 | ||
| Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of Swedish Rectal Cancer Trial | Q33593850 | ||
| Survival from acute non-lymphocytic leukaemia, 1971-88: a population based study. | Q33624440 | ||
| Barriers to participation in randomised controlled trials: a systematic review | Q33784129 | ||
| Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial | Q33813436 | ||
| Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice | Q33883777 | ||
| Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". | Q33935724 | ||
| Systematic review to determine whether participation in a trial influences outcome | Q33940563 | ||
| Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205 | Q34049250 | ||
| Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer | Q34226107 | ||
| The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity | Q68879882 | ||
| Survival in childhood acute lymphocytic leukemia: effect of protocol and place of treatment | Q70929334 | ||
| Cooperative groups and community hospitals. Measurement of impact in the community hospitals | Q71030005 | ||
| Duration of survival of children with acute leukaemia. Report to the Medical Research Council from the Committee on Leukaemia and the Working Party on Leukaemia in Childhood | Q71066851 | ||
| Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies | Q71109928 | ||
| Limited-stage small-cell lung cancer: patient survival after combined chemotherapy and radiation therapy with and without treatment protocols | Q71539577 | ||
| Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study | Q72816337 | ||
| Hazard function estimators: a simulation study | Q73139252 | ||
| Underrepresentation of patients 65 years of age or older in cancer-treatment trials | Q73311140 | ||
| Factors influencing enrollment in clinical trials for cancer treatment | Q73332780 | ||
| Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix | Q73675166 | ||
| Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study | Q74784116 | ||
| Bilateral orchiectomy with or without flutamide for metastatic prostate cancer | Q77374114 | ||
| How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials | Q77948975 | ||
| Participation in cancer clinical trials: race-, sex-, and age-based disparities | Q80179103 | ||
| Econometrics in outcomes research: the use of instrumental variables | Q34470348 | ||
| Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer | Q34520088 | ||
| Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study | Q34528336 | ||
| Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0 | Q34743442 | ||
| Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a randomized clinical chemotherapy trial | Q34974888 | ||
| Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994. | Q35264729 | ||
| Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia | Q35624603 | ||
| Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review | Q35642930 | ||
| Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland | Q35717998 | ||
| A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. | Q35733207 | ||
| Protocol allocation and exclusion in two Danish randomised trials in ovarian cancer | Q35994277 | ||
| The selection of cases for randomised trials: a registry survey of concurrent trial and non-trial patients. The British Stomach Cancer Group | Q35994589 | ||
| Centralised treatment, entry to trials and survival | Q36079975 | ||
| A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). | Q36251468 | ||
| Patterns of care and survival for adolescents and young adults with acute leukaemia--a population-based study | Q36618262 | ||
| Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer: response and survival results | Q36646034 | ||
| After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer | Q36673971 | ||
| Results of a breast-cancer-surgery trial compared with observational data from routine practice. | Q36796452 | ||
| Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review | Q37002937 | ||
| Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research | Q39452746 | ||
| Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations | Q40618389 | ||
| Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group | Q40646286 | ||
| Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma | Q40701794 | ||
| Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of cooperative group (ECOG) participation | Q40814300 | ||
| Childhood NHL in Switzerland: incidence and survival of 120 study and 42 non-study patients | Q40986766 | ||
| Reducing patient eligibility criteria in cancer clinical trials | Q40997268 | ||
| Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials | Q43458445 | ||
| Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials | Q43576436 | ||
| Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial | Q43658480 | ||
| Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study | Q44962370 | ||
| Hazard rate estimation under random censoring with varying kernels and bandwidths | Q46063147 | ||
| Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study | Q46130550 | ||
| Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group | Q46244025 | ||
| Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. | Q46856631 | ||
| Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials | Q50120629 | ||
| Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). | Q50696600 | ||
| Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. | Q51943059 | ||
| Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician's Patient Log. | Q52595617 | ||
| Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole. | Q52915059 | ||
| Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994. | Q53540758 | ||
| Selection bias in clinical trials of anaplastic glioma. | Q55485061 | ||
| Long-term survival in Hodgkin's disease patients | Q62583519 | ||
| Nephroblastoma: treatment during 1970-3 and the effect on survival of inclusion in the first MRC trial | Q66850986 | ||
| P6195 | funding scheme | grant | Q230788 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | demography | Q37732 |
| patient | Q181600 | ||
| P5008 | on focus list of Wikimedia project | Wikimedia–NIOSH collaboration | Q104416361 |
| P304 | page(s) | dju002 | |
| P12526 | performing organization | University of Washington | Q219563 |
| P577 | publication date | 2014-03-01 | |
| 2014-03-13 | |||
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P859 | sponsor | National Institute for Occupational Safety and Health | Q60346 |
| P1476 | title | Comparison of survival outcomes among cancer patients treated in and out of clinical trials | |
| P478 | volume | 106 |
| Q28551817 | A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials |
| Q36759996 | A randomized phase II dose-response exercise trial among colon cancer survivors: Purpose, study design, methods, and recruitment results. |
| Q41669687 | A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden |
| Q38502885 | Adolescent and young adult patients with cancer: a milieu of unique features |
| Q57806337 | Adult leukemia survival trends in the United States by subtype: A population-based registry study of 370,994 patients diagnosed during 1995-2009 |
| Q43638078 | Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials |
| Q64118721 | Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation |
| Q89120053 | Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies |
| Q33740600 | Can quality of life assessments differentiate heterogeneous cancer patients? |
| Q40071391 | Characteristics and outcome of patients with primary CNS lymphoma in a "real-life" setting compared to a clinical trial |
| Q55002577 | Clinical trial insurance coverage for cancer patients under the Affordable Care Act. |
| Q90154343 | Clinical trials-Designing, implementing, and collaborating |
| Q37744801 | Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma |
| Q35793038 | Comparative effectiveness research in gynecologic oncology |
| Q36055266 | Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial |
| Q40895560 | Comparison of clinical trial versus non-clinical trial treatment outcomes of childhood acute lymphoblastic leukemia using comparable regimens |
| Q93032023 | Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden |
| Q49928907 | Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. |
| Q53280595 | Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. |
| Q89491824 | Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patients |
| Q35223735 | Drugs, cancer and end-of-life care: a case study of pharmaceuticalization? |
| Q38822583 | Early mortality and overall survival of acute myeloid leukemia based on facility type |
| Q38730792 | Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature |
| Q30871265 | Enhancing cancer registry data for comparative effectiveness research (CER) project: overview and methodology. |
| Q57020360 | Enrollment on clinical trials does not improve survival for children with acute myeloid leukemia: A population-based study |
| Q91872594 | Extent of Exclusions for Chronic Conditions in Breast Cancer Trials |
| Q96433616 | Externally Controlled Trials: Are We There Yet? |
| Q36176911 | From evidence to clinical practice in blood and marrow transplantation |
| Q59349292 | Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer |
| Q64118478 | Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials |
| Q90364578 | Guy's cancer cohort - real world evidence for cancer pathways |
| Q35930475 | How much do cancer-related symptoms contribute to health-related quality of life in lung and colorectal cancer patients? A report from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium |
| Q92326302 | Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice |
| Q48124116 | Improving the accrual of racial and ethnic minority patients in clinical trials: Time to raise the stakes. |
| Q90010770 | Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity research |
| Q33660380 | International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer |
| Q54996768 | Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib? |
| Q40122611 | Malignant central nervous system tumors among adolescents and young adults (15-39 years old) in 14 Southern-Eastern European registries and the US Surveillance, Epidemiology, and End Results program: Mortality and survival patterns. |
| Q39547691 | Non-recruitment to and selection bias in studies using echocardiography in hemodialysis patients |
| Q93101356 | Oncology clinical trials and insurance coverage: An update in a tenuous insurance landscape |
| Q90277210 | Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System |
| Q95843485 | Outcomes among pediatric patients with cancer who are treated on trial versus off trial: A matched cohort study |
| Q38338989 | Outcomes and endpoints in cancer trials: bridging the divide |
| Q38251598 | Pemetrexed for ovarian cancer: a systematic review of the published literature and a consecutive series of patients treated in a nonclinical trial setting |
| Q55361068 | Perceptions and attitudes toward clinical trials in adolescent and young adults with cancer: a systematic review. |
| Q34921738 | Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers |
| Q55712411 | Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey☆. |
| Q38367168 | Renal effects of targeted anticancer therapies |
| Q90425225 | Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States |
| Q48165118 | Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials |
| Q98891911 | Survival following upfront chemotherapy for treatment-naïve metastatic prostate cancer: a real-world retrospective cohort study |
| Q39417841 | Telehealth models could be extended to conducting clinical trials-a teletrial approach |
| Q38375972 | The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population |
| Q33865329 | The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies |
| Q37095602 | The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials |
| Q45941138 | The VITAL study: case control studies are hypothesis-generating. |
| Q41690271 | The challenges of symptom management for patients with multimorbidity in research and practice: a thematic review |
| Q38419183 | The future of trials in surgical oncology. |
| Q46093492 | Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes |
| Q91163023 | Unplanned hospitalizations in a racially and ethnically diverse population of women receiving chemotherapy for epithelial ovarian cancer |
| Q36011137 | Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer |
| Q33816983 | Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer |
| Q36932625 | Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer |
| Q38832807 | Why take part in personalised cancer research? Patients' genetic misconception, genetic responsibility and incomprehension of stratification-an empirical-ethical examination |
Search more.